Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment.

MLA

Wen, Qing, et al. “Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment.” Pharmaceutics, vol. 17, no. 1, Jan. 2025, p. 99. EBSCOhost, https://doi.org/10.3390/pharmaceutics17010099.

APA

Wen, Q., Karcher, H., Wright, D. M., Sinha, S. B., Chakravarthy, U., Santos, C., Igwe, F., Salongcay, R., Curran, K., & Peto, T. (2025). Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment. Pharmaceutics, 17(1), 99. https://doi.org/10.3390/pharmaceutics17010099

Chicago

Wen, Qing, Helene Karcher, David M. Wright, Samriddhi Buxy Sinha, Usha Chakravarthy, Catarina Santos, Franklin Igwe, Recivall Salongcay, Katie Curran, and Tunde Peto. 2025. “Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment.” Pharmaceutics 17 (1): 99. doi:10.3390/pharmaceutics17010099.